WO2022215032 - NOVEL DARPIN BASED CD70 ENGAGERS
National phase entry:
Publication Number
WO/2022/215032
Publication Date
13.10.2022
International Application No.
PCT/IB2022/053275
International Filing Date
07.04.2022
Title **
[English]
NOVEL DARPIN BASED CD70 ENGAGERS
[French]
NOUVEAUX AGENTS DE MISE EN CONTACT DE CD70 À BASE DE DARPIN
Applicants **
MOLECULAR PARTNERS AG
Inventors
REICHEN, Christian
RESCHKE, Nina
SCHLERETH, Bernd
Priority Data
63/172,973
09.04.2021
US
63/173,186
09.04.2021
US
63/265,181
09.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2811 | |
| EPO | Filing, Examination, Granting | 16780 | |
| Japan | Filing, Examination, Granting | 2618 | |
| South Korea | Filing, Examination, Granting | 3081 | |
| USA | Filing, Examination, Granting | 8540 |
Total:
33,830
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to recombinant binding proteins comprising an ankyrin repeat domain, wherein the ankyrin repeat domain has binding specificity for human CD70. in addition, the invention relates to nucleic acids encoding such recombinant binding proteins, pharmaceutical compositions comprising such proteins or nucleic adds, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, such as cancer, e g,, acute myeloid leukemia (AML), in a mammal, including a human.[French]
La présente invention concerne des protéines de liaison recombinées comprenant un domaine de répétition d'ankyrine, le domaine de répétition d'ankyrine ayant une spécificité de liaison pour le CD70 humain. De plus, l'invention concerne des acides nucléiques codant de telles protéines de liaison recombinées, des compositions pharmaceutiques comprenant de telles protéines ou des acides nucléiques, et l'utilisation de telles protéines de liaison, d'acides nucléiques ou de compositions pharmaceutiques dans des méthodes de traitement ou de diagnostic de maladies, telles que le cancer, par exemple, la leucémie myéloïde aiguë (AML) chez un mammifère, y compris un être humain.